Board of Directors

Mr. Welborn is Senior Advisor, Stadium Capital Management, LLC, an investment advisory firm. His extensive investment and advisory background includes work with The Beacon Group, LLC, which is now part of J.P. Morgan Chase & Co. He also served on the Boards of Intermountain Community Bancorp, Panhandle State Bank, Inc., and Ascena Retail Group, Inc. and was a Board observer at West Coast Bancorp. Mr. Welborn holds a BS degree in Commerce, with concentrations in Finance and Accounting, from the McIntire School of Commerce at the University of Virginia.

Mr. Millian is a pharmaceutical executive with an exceptional depth and breadth of experience at commercial and clinical stage biopharma companies. Most recently, he served as the Chief Operating Officer at Corbus Pharmaceuticals, contributing to its organizational transformation. Craig previously held leadership positions at EMD Serono, the US affiliate of Merck KGaA, where he was the Senior Vice President with P&L responsibility for several specialty business units including endocrinology and neurology / immunology. As Vice President, Commercial, at Vertex Pharmaceuticals, he helped design and build commercial infrastructure, organizational capabilities, and go-to-market strategies. Early in his career, he held marketing leadership roles for several blockbuster brands at both Pfizer Inc. and Sanofi. Craig earned an MBA from New York University and his undergraduate degree in finance from the University of Pennsylvania..

Ms. Beauchamp is corporate director with over 30 years of health care experience in corporate and non-profit organizations, including executive positions at Bayer Healthcare (Canada and Global) and Sanofi Canada. Ms. Beauchamp serves on the Boards of Aurora Cannabis Inc. (TSX:ACB) (“Aurora”), as Chair of its Nominating and Corporate Governance Committee and a member of its Human Resources and Compensation Committee, Extendicare Inc. (TSX:EXE), as a member of the Investment Committee and the Quality and Risk Committee, and Dialogue Health Technologies Inc. (TSX:CARE), a leading telehealth service. Formerly, Ms. Beauchamp served on the Board of MedReleaf Corp., prior to its acquisition by Aurora. Ms. Beauchamp also serves as a member of the National Research Council of Canada, is on the Board of the Ontario Caregiver Organization, and is a Regional Ambassador with Women Get on Board. Ms. Beauchamp has completed the University of Toronto’s Rotman School of Management Directors Education Program (ICD.D) and holds a Bachelor of Business Administration in Marketing from Bishop’s University.

Mr. DeLong has more than 25 years of scientific, operations, business development, and strategic leadership experience in the biopharmaceutical industry. During his tenure at Apellis Pharmaceuticals, most recently as Chief Business & Strategy Officer, he played a key role in the company's evolution into a commercial organization and in Apellis's $5.6 billion acquisition by Biogen, having helped guide the company from development through regulatory approval, commercialization, and ultimately its strategic exit. He currently serves as Chief Executive Officer of Arrakis Therapeutics, a clinical-stage biopharmaceutical company. Mr. DeLong holds a B.Sc. in chemical engineering from Penn State University and an M.B.A. from the University of Michigan.

Mr. Hanna is a finance executive with 20+ years working with C-level Executives and board members of public companies. Before joining HLS Therapeutics, he was CFO at Inca Networks Inc. During his 10-year tenure as CFO of Vecima Networks Inc. (TSX:VCM), he held operational P&L responsibility and monetized non-core assets while acquiring strategic assets to grow the business. Earlier, Mr. Hanna held senior financial positions with The Westaim Corporation (TSX:WED), including VP of Corporate Development with Westaim Biomedical Corp. He holds an MBA from the University of British Columbia and a BSc from the University of Victoria. Mr. Hanna is also a designated accountant and has served as a corporate board member for venture-backed technology companies, including Vector 12 and LTG Lasertech.

Mr. Hill is Global Head of Technology, Data and Security Ontario Municipal Employees Retirement System Administration Corporation (“OMERS”). He has more than 30 years of experience in business management, risk management, technology, finance, and accounting. Mr. Hill joined OMERS in 2011 as EVP & Chief Auditor, and in 2015 was appointed to serve as OMERS first Chief Risk Officer. He moved into his current role in 2023. Mr. Hill previously worked at PriceWaterhouseCoopers for 22 years, the last 10 of which as a Partner specializing in auditing complex public and private companies in a variety of sectors, including pharmaceuticals.

Dr. Maxwell is a physician-executive, investor, and experienced public company director. She is a director of ImmunityBio, Inc. (Nasdaq: IBRX), where she chairs the Compensation Committee and serves on the Audit and Related Party Transactions Committees. She is also a director of United Therapeutics Corporation (Nasdaq: UTHR), where she serves on the Compensation and Nominating and Governance Committees. Dr. Maxwell is an Operating Partner at DCVC, a Silicon Valley venture capital firm, where she brings senior strategic and investment judgment to prospective opportunities and portfolio companies, including through service on select company boards. Dr. Maxwell earned an A.B. from Harvard University, an M.D. from Yale University and an M.B.A. from the University of Oxford.

Mr. Roy is a healthcare industry consultant with 30 years of experience with multinational corporations and as an entrepreneur. He is a former Partner and Executive Vice President of the Healthcare division at TANK Worldwide Inc. until it was acquired by WPP plc in June 2022. Prior to joining TANK in 2013, Mr. Roy spent more than 20 years in the pharmaceutical industry, including as Vice President of Marketing for Pfizer in Canada from 2008 to 2013. He has broad experience working on projects in Canada, the United States, Europe, and Asia. Mr. Roy holds a Bachelor of Chemical Engineering from University of Sherbrooke.